Phase 1 Cardiomyopathy Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have a weakened heart (reduced pumping ability of 40% or less) that was caused by chemotherapy drugs called anthracyclines, used to treat any type of cancer, at any dose and at any point in the past, with no other known cause for the heart weakness.
- You are between 18 and 90 years old. Both English and non-English speakers are welcome.
- Your heart failure symptoms have been classified by a doctor as mild, moderate, or noticeable but not severe (NYHA Class I, II, or III — confirm with trial site if unsure which applies to you).
- If you were also treated with the drug trastuzumab (Herceptin), your heart must still be showing weakness at least 90 days after stopping that treatment.
- You are able to complete a 6-minute walking test.
- You have already been treated with the best available standard medicines for heart failure.
- You, or someone legally authorised to act on your behalf, are able to sign a consent form.
Who may not be able to join:
- You have been diagnosed with heart disease caused by blocked or narrowed arteries, as confirmed by a heart specialist.
- You have a significant heart valve problem (such as a severely narrowed or leaking valve — confirm with trial site).
- You have a family history of inherited heart muscle disease.
- You have had heart muscle inflammation (myocarditis) within the past 2 months.
- You have a history of heart muscle disease caused by a substance building up in the heart, or a stiffening of the heart muscle (confirm with trial site).
- A blood clot has been found inside the left side of your heart, as shown by a heart scan.
- Your liver is not functioning well — specifically, certain liver test results are more than 3 times higher than the normal range.
- Your heart failure symptoms are classified as very severe (NYHA Class IV — confirm with trial site).
- You rely on medication given through a drip to keep your heart pumping.
- You have a dangerous or unstable irregular heartbeat.
- If you are not taking blood-thinning medication, your blood clotting level (INR) is above 1.5 (confirm with trial site).
- You have an artificial or donor tissue heart valve.
- Your heart is in a state of crisis and cannot pump enough blood to the body (cardiogenic shock).
- You are currently pregnant or breastfeeding.
- You have an autoimmune condition and are currently taking medication that suppresses your immune system.
- You have an active infection that is not responding to treatment, as assessed by the trial doctor.
- You have received trastuzumab (Herceptin) within the last 3 months.
- You have had an internal heart defibrillator device (AICD) implanted within the last 30 days.
- Your internal heart defibrillator (AICD) has delivered a shock within the last 30 days.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Amanda Olson, MD, M.D. Anderson Cancer Center
Phone: 713-745-3055
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence of adverse events; Change in left ventricular ejection fraction (LVEF)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.